Trial Profile

A Phase I Study of SBRT Vaccination With Atezolizumab and Bevacizumab for Patients With Advanced Hepatocellular Carcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
Indications Carcinoma; Liver cancer
Focus Adverse reactions

Most Recent Events

10 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2026.
21 Jan 2023 According to the trial design presented at 2023 Gastrointestinal Cancers Symposium, complete accrual is expected by June 2024.
21 Jan 2023 Trial design presented at 2023 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com